Arcutis Biotherapeutics (ARQT) Short Interest Ratio & Short Volume → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ARQT Stock Alerts $9.20 +0.08 (+0.88%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Arcutis Biotherapeutics Short Interest DataCurrent Short Volume21,690,000 sharesPrevious Short Volume19,660,000 sharesChange Vs. Previous Month+10.33%Dollar Volume Sold Short$180.46 millionShort Interest Ratio / Days to Cover5.7Last Record DateApril 30, 2024Outstanding Shares115,760,000 sharesPercentage of Shares Shorted18.74%Today's Trading Volume3,450,500 sharesAverage Trading Volume4,425,614 sharesToday's Volume Vs. Average78% Short Selling Arcutis Biotherapeutics ? Sign up to receive the latest short interest report for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatARQT Short Interest Over TimeARQT Days to Cover Over TimeARQT Percentage of Float Shorted Over Time Ad InvestorPlaceMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… Arcutis Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202421,690,000 shares $180.46 million +10.3%N/A5.7 $8.32 4/15/202419,660,000 shares $198.37 million +2.1%N/A4.3 $10.09 3/31/202419,260,000 shares $190.87 million +28.5%N/A4 $9.91 3/15/202414,990,000 shares $159.79 million -5.0%N/A2.8 $10.66 2/29/202415,780,000 shares $162.22 million -6.9%N/A2.6 $10.28 2/15/202416,940,000 shares $135.01 million +1.0%N/A2.9 $7.97 Get the Latest News and Ratings for ARQT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202416,780,000 shares $98.50 million -19.4%N/A3.1 $5.87 1/15/202420,830,000 shares $75.82 million +3.2%N/A4.1 $3.64 12/31/202320,180,000 shares $65.18 million +3.7%N/A4.2 $3.23 12/15/202319,460,000 shares $47.48 million -6.9%N/A4.8 $2.44 11/30/202320,900,000 shares $38.46 million +19.4%N/A8.2 $1.84 11/15/202317,510,000 shares $36.42 million +2.6%N/A8 $2.08 10/31/202317,070,000 shares $38.41 million +21.4%N/A8.5 $2.25 10/15/202314,060,000 shares $54.55 million +8.3%N/A8.7 $3.88 9/30/202312,980,000 shares $68.92 million -2.3%29.0%12.1 $5.31 9/15/202313,280,000 shares $90.44 million +6.4%29.7%13.1 $6.81 8/31/202312,480,000 shares $106.58 million -19.2%27.9%11.3 $8.54 8/15/202315,450,000 shares $130.86 million +1.6%34.5%12.8 $8.47 7/31/202315,210,000 shares $165.94 million +3.1%33.9%12.3 $10.91 7/15/202314,760,000 shares $139.33 million +0.2%32.8%11.9 $9.44 6/30/202314,730,000 shares $140.38 million +12.5%32.8%11.3 $9.53 6/15/202313,090,000 shares $133.78 million +0.4%29.1%10 $10.22 5/31/202313,040,000 shares $97.93 million -13.1%29.1%10.3 $7.51 5/15/202315,010,000 shares $154.60 million -2.5%33.7%13.1 $10.30 4/30/202315,390,000 shares $213.00 million +0.3%35.2%15.6 $13.84 4/15/202315,350,000 shares $213.21 million +1.5%35.1%15.5 $13.89 3/31/202315,120,000 shares $166.32 million +10.0%34.5%15.4 $11.00 3/15/202313,750,000 shares $152.76 million +11.1%31.4%14.9 $11.11 2/28/202312,380,000 shares $200.31 million +4.2%28.2%15 $16.18 2/15/202311,880,000 shares $203.62 million +10.1%27.2%15 $17.14 1/31/202310,790,000 shares $178.79 million +0.5%25.0%13 $16.57 1/15/202310,740,000 shares $151.65 million +0.9%24.9%13.1 $14.12 12/30/202210,650,000 shares $157.62 million +6.8%24.7%13.9 $14.80 12/15/20229,970,000 shares $164.41 million +5.1%23.1%12.7 $16.49 11/30/20229,490,000 shares $163.51 million +17.9%22.0%12.6 $17.23 11/15/20228,050,000 shares $156.49 million +0.1%18.7%10.8 $19.44 10/31/20228,040,000 shares $142.15 million +17.4%19.2%12.1 $17.68 10/15/20226,850,000 shares $127.68 million +14.4%16.4%9.1 $18.64 9/30/20225,990,000 shares $114.47 million +15.2%14.3%8.6 $19.11 9/15/20225,200,000 shares $97.19 million +1.6%12.5%7.7 $18.69Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… ARQT Short Interest - Frequently Asked Questions What is Arcutis Biotherapeutics' current short interest? Short interest is the volume of Arcutis Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 21,690,000 shares of ARQT short. Learn More on Arcutis Biotherapeutics' current short interest. What is a good short interest ratio for Arcutis Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARQT shares currently have a short interest ratio of 6.0. Learn More on Arcutis Biotherapeutics's short interest ratio. Which institutional investors are shorting Arcutis Biotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arcutis Biotherapeutics: StemPoint Capital LP, Concourse Financial Group Securities Inc., and Perceptive Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Arcutis Biotherapeutics' short interest increasing or decreasing? Arcutis Biotherapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 21,690,000 shares, an increase of 10.3% from the previous total of 19,660,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Arcutis Biotherapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Arcutis Biotherapeutics: Ocular Therapeutix, Inc. (13.61%), Liquidia Co. (10.62%), Bicycle Therapeutics plc (6.52%), Centessa Pharmaceuticals plc (2.99%), OPKO Health, Inc. (26.42%), Tyra Biosciences, Inc. (11.01%), 89bio, Inc. (10.93%), Immunome, Inc. (4.42%), ABIVAX Société Anonyme (0.12%), ARS Pharmaceuticals, Inc. (15.81%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Arcutis Biotherapeutics stock? Short selling ARQT is an investing strategy that aims to generate trading profit from Arcutis Biotherapeutics as its price is falling. ARQT shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcutis Biotherapeutics? A short squeeze for Arcutis Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ARQT, which in turn drives the price of the stock up even further. How often is Arcutis Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARQT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Ocular Therapeutix Short Squeeze Liquidia Short Squeeze Bicycle Therapeutics Short Squeeze Centessa Pharmaceuticals Short Squeeze OPKO Health Short Squeeze Tyra Biosciences Short Squeeze 89bio Short Squeeze Immunome Short Squeeze ABIVAX Société Anonyme Short Squeeze ARS Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARQT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club